Stocks
Leerink Partners Boosts Merck & Co Target to $161 Amid Bullish Stance
Leerink Partners has reaffirmed its 'Buy' rating for Merck & Co (MRK.US) and raised its target price to $161.
The analysts at Leerink Partners, specifically Daina Graybosch, maintain a bullish stance on the pharmaceutical company. Graybosch's adjusted target price is now higher than the previous estimate of $114.
While TipRanks data suggests that Graybosch has a success rate of 38.9% and an average return of -7.5% over the past year, Leerink Partners remains confident in its rating.